Ignite Creation Date:
2025-12-24 @ 1:06 PM
Ignite Modification Date:
2026-01-01 @ 9:12 AM
Study NCT ID:
NCT00431561
Status:
COMPLETED
Last Update Posted:
2013-12-03
First Post:
2007-02-05
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Phase IIb Clinical Trial With TGF-β2 Antisense Compound AP 12009 for Recurrent or Refractory High-grade Glioma
Sponsor:
Isarna Therapeutics GmbH
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2003-04
Start Date Type:
None
Primary Completion Date:
2009-03
Primary Completion Date Type:
ACTUAL
Completion Date:
2009-03
Completion Date Type:
ACTUAL
First Submit Date:
2007-02-05
First Submit QC Date:
None
Study First Post Date:
2007-02-06
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2013-12-02
Last Update Post Date:
2013-12-03
Last Update Post Date Type:
ESTIMATED